<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274309</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.388</org_study_id>
    <secondary_id>2019-A03333-54</secondary_id>
    <nct_id>NCT04274309</nct_id>
  </id_info>
  <brief_title>Safety Validation of EndoSWIR Device</brief_title>
  <acronym>ENDO-AMYG</acronym>
  <official_title>Evaluation of the Medical Device ex Vivo ENDOSWIR in Patient Operated for a Tonsillectomy : a Preliminary Cohort Study Proof of Concept (ENDOSWIR-AMYG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé et de la Recherche Médicale, Institute for Advanced Biosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lynred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Head and neck cancer has an incidence of 600,000 cases per year worldwide (6th among cancers)
      and cause 380,000 death per year. Surgical resection is guided by the surgeon's inspection
      and palpation of the tumor. The prognosis of patients depends on the quality of the lesion's
      resection. The ENDOSWIR dispositive developed by engineers of Atomic Energy Comity of
      Grenoble allows for reliable and accurate analysis of tumor margins.

      The camera provides a spectral analysis of the tissues according to their composition. We
      want to show that the prognosis of patients is improved by the use of this device. For that
      we need to prove first that it is not toxic for tissue analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ENDOSWIR dispositive is a InGaAs (Indium Gallium Arsenide) camera working at ambient
      temperature. The light is a quartz-tungstene-halogeno (QTH) source and the collected beam is
      filtered to illuminate in different precise wavelength bands in the short wave domain.

      We will use it on tonsil tissue just after tonsillectomy and just before the histological
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Tissue integrity</measure>
    <time_frame>1 day</time_frame>
    <description>Histological score : evaluation of cellular cohesion and denaturation of epithelial cells and conjunctive support tissue</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Optical Guided Surgery</condition>
  <arm_group>
    <arm_group_label>Patient's tissues exposed</arm_group_label>
    <description>Tonsil of each patient will be imaged using the medical device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient's tissues not exposed</arm_group_label>
    <description>Tonsil of each patient will not be imaged using the medical device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoSWIR</intervention_name>
    <description>Exposition of the respected tissues to the camera</description>
    <arm_group_label>Patient's tissues exposed</arm_group_label>
    <arm_group_label>Patient's tissues not exposed</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men or Women more than 18
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tonsillectomy

        Exclusion Criteria:

          -  suspicion of Head-and neck cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian RIGHINI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian RIGHINI</last_name>
    <phone>04 76 76 56 56</phone>
    <phone_ext>+33</phone_ext>
    <email>crighini@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noémie DUTRIEUX</last_name>
    <phone>04 76 76 56 56</phone>
    <phone_ext>+33</phone_ext>
    <email>ndutrieux@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémie DUTRIEUX</last_name>
      <phone>04767656 56</phone>
      <phone_ext>+33</phone_ext>
      <email>ndutrieux@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

